Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs

(2022) André E. Nel et al.   ACS Nano

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

(2022) Zhilin Li et al.   Advanced Science

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

(2021) Xiangsheng Liu et al.   Advanced Science

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future

(2021) Razan Alzeibak et al.   Journal for ImmunoTherapy of Cancer

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

(2021) Sachin Bhagchandani et al.   ADVANCED DRUG DELIVERY REVIEWS

Lymph-Node-Targeted Cholesterolized TLR7 Agonist Liposomes Provoke a Safe and Durable Antitumor Response

(2021) Dandan Wan et al.   NANO LETTERS

Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer

(2020) Samarth Hegde et al.   CANCER CELL

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

(2020) James E. Frampton   DRUGS

3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

(2020) Sudhir Pai Kasturi et al.   Science Immunology

FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets

(2020) Reem Saleh et al.   CANCER LETTERS

Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy

(2019) Yinchu Ma et al.   ACS Nano

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

(2019) Stefanie R. Mullins et al.   Journal for ImmunoTherapy of Cancer

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

(2019) Katherine A. Michaelis et al.   Nature Communications

Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation

(2018) Jérôme Widmer et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance

(2018) Melissa A. Meyer et al.   Nature Communications

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

(2018) Christopher B. Rodell et al.   Nature Biomedical Engineering

Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer

(2018) Xiangsheng Liu et al.   ACS Nano

3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine

(2017) Qian Wang et al.   JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS

Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer

(2016) Xiangsheng Liu et al.   ACS Nano

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

(2016) Christopher B. Fox et al.   JOURNAL OF CONTROLLED RELEASE

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice

(2015) Huan Meng et al.   ACS Nano

Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma

(2015) Martin Wartenberg et al.   Oncotarget

Corrigendum: “Combinatorial Strategies for the Induction of Immunogenic Cell Death”

(2015) Lucillia Bezu et al.   Frontiers in Immunology

Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells

(2014) Moonkyu Lee et al.   ARCHIVES OF PHARMACAL RESEARCH

Crosstalk between ER stress and immunogenic cell death

(2013) Oliver Kepp et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

(2011) Dmitri Smirnov et al.   VACCINE

The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system

(2011) Abbi L Engel et al.   Expert Review of Clinical Pharmacology

Pattern Recognition Receptors and Inflammation

(2010) Osamu Takeuchi et al.   CELL

Toll-like receptors — taking an evolutionary approach

(2008) François Leulier et al.   NATURE REVIEWS GENETICS